Curated News
By: NewsRamp Editorial Staff
September 09, 2026
Nutriband CEO to Speak at Nasdaq Biotech Summit
TLDR
- Nutriband CEO attends Nasdaq Biotech Summit, positioning the company for key investor connections and potential partnerships.
- Nutriband's AVERSA technology prevents drug abuse, misuse, diversion, and accidental exposure in transdermal patches.
- Nutriband's abuse-deterrent fentanyl patch aims to reduce opioid addiction and accidental exposure, improving patient safety.
- Nutriband's CEO will speak at the inaugural Nasdaq Biotech Summit in New York on Sept. 16, 2026.
Impact - Why it Matters
Nutriband's participation in the Nasdaq LaB Biotech Summit highlights its ongoing efforts to combat opioid abuse through its AVERSA™ technology. This event provides a unique opportunity for the company to gain visibility among investors and industry leaders, potentially accelerating partnerships and funding for its innovative transdermal products. For the broader biotech community, Nutriband's presence underscores the growing importance of abuse-deterrent technologies in addressing public health crises. The summit also serves as a networking hub that could influence future collaborations and market trends in the biotech sector, making it a significant event for stakeholders to watch.
Summary
Nutriband (NASDAQ: NTRB), a pharmaceutical company specializing in transdermal drug delivery, announced that its CEO, Gareth Sheridan, will attend the inaugural Nasdaq LaB Biotech Summit on September 16, 2026, at the Nasdaq MarketSite in New York. The summit brings together biotechnology executives, investors, and industry leaders for an evening of thought leadership and networking, providing Nutriband with a platform to showcase its innovations and connect with key stakeholders in the biotech sector.
Nutriband is primarily focused on developing a portfolio of transdermal pharmaceutical products, with its lead product being an abuse-deterrent fentanyl patch that incorporates its proprietary AVERSA™ technology. This technology is designed to be integrated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The company's participation in the summit underscores its commitment to addressing the opioid crisis through innovative safety features.
The news was distributed by BioMedWire (BMW), a specialized communications platform that covers the biotech, biomedical, and life sciences sectors. BMW is part of the Dynamic Brand Portfolio at IBN, which offers a range of services including press release distribution, editorial syndication to over 5,000 outlets, and social media reach. Investors and industry observers can follow Nutriband's latest updates through its newsroom at https://ibn.fm/NTRB. For more details on the press release, visit https://ibn.fm/j4F3R.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Nutriband CEO to Speak at Nasdaq Biotech Summit
